BIND Therapeutics, a clinical-stage biotech developing a platform of targeted and programmable therapeutics for the treatment of cancer and other diseases, filed on Monday with the SEC to raise up to $81 million in an initial public offering. The Cambridge, MA-based company, which was founded in 2006 and booked $2 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol BIND. BIND Therapeutics initially filed confidentially on June 28, 2013. Credit Suisse and Cowen & Company are the joint bookrunners on the deal. No pricing terms were disclosed.
